Stemtech Corporation (STEK) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stemtech Corporation (STEK) trades at $0.0001. Stemtech Corporation develops and markets stem cell nutrition products aimed at supporting the body's natural renewal processes. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for STEK: STEK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates STEK against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on STEK.
How is this calculated? →Stemtech Corporation (STEK) Healthcare & Pipeline Overview
Stemtech Corporation develops and distributes stem cell nutrition products, differentiating itself through science-based formulations targeting stem cell physiology. With a focus on the Americas, Latin America, and Asia, the company operates in the competitive dietary supplement market, facing challenges typical of OTC-traded healthcare firms.
What Is the Investment Thesis for STEK?
Stemtech Corporation operates in the niche market of stem cell nutrition, offering potential for growth within the broader dietary supplement industry. With a market capitalization of $0.00B and a negative P/E ratio of -0.01, the company's financial performance indicates challenges. A gross margin of 80.4% suggests strong pricing power, but a profit margin of -79.2% highlights significant operational inefficiencies. Growth catalysts include expanding distribution networks in the Americas, Latin America, and Asia, and introducing new science-backed products. Potential risks include competition from established dietary supplement brands and the regulatory scrutiny typical of the healthcare sector. Investors should closely monitor Stemtech's ability to improve profitability and manage its operational costs.
Based on FMP financials and quantitative analysis
STEK Key Highlights
Market Cap of $0.00B reflects the company's small size and potential volatility.
- P/E Ratio of -0.01 indicates the company is currently not profitable.
- Gross Margin of 80.4% demonstrates strong pricing power in its niche market.
- Profit Margin of -79.2% highlights significant operational challenges and cost management issues.
- Beta of 2.31 suggests the stock is more volatile than the market.
Who Are STEK's Competitors?
STEK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| ETST Earth Science Tech, Inc. | $0.11 | +29.41% | $31.7M | 61 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STEK's Key Strengths?
Science-based product formulations.
- Established brand recognition in niche market.
- Focus on stem cell nutrition.
- Presence in multiple geographic regions.
What Are STEK's Weaknesses?
Negative profit margin.
- Small market capitalization.
- Limited financial resources.
- Dependence on a niche market.
What Could Drive STEK Stock Higher?
Potential expansion of distribution agreements in key markets.
- Continued investment in research and development of new products.
- Efforts to improve operational efficiency and reduce costs.
What Are the Key Risks for STEK?
Financial-distress signal — its Altman Z-Score of -21.89 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Increased competition from established dietary supplement brands.
- Regulatory changes affecting the dietary supplement industry.
- Operational inefficiencies impacting profitability.
- Limited financial resources hindering growth initiatives.
What Are the Growth Opportunities for STEK?
- Expanding Distribution Networks: Stemtech can increase its market reach by expanding its distribution networks in the Americas, Latin America, and Asia. This includes partnering with local retailers, distributors, and online platforms to make its products more accessible to consumers. The global dietary supplement market is projected to reach $230.73 billion by 2027, providing a substantial market opportunity for Stemtech to capture. Timeline: Ongoing.
- Introducing New Science-Backed Products: Stemtech can drive growth by investing in research and development to introduce new science-backed products that address specific health needs. This includes developing formulations that target different aspects of stem cell physiology and conducting clinical trials to validate their efficacy. The market for science-backed dietary supplements is growing, driven by increasing consumer demand for evidence-based health solutions. Timeline: Ongoing.
- Leveraging Online Marketing and E-Commerce: Stemtech can enhance its brand awareness and drive sales by leveraging online marketing and e-commerce channels. This includes creating engaging content, running targeted advertising campaigns, and optimizing its online store for conversions. The global e-commerce market is projected to reach $6.2 trillion in 2024, providing a significant opportunity for Stemtech to expand its online presence. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Stemtech can accelerate its growth by forming strategic partnerships and collaborations with other companies in the healthcare and wellness industries. This includes partnering with research institutions, healthcare providers, and fitness centers to promote its products and reach new customers. The market for strategic partnerships in the healthcare industry is growing, driven by the need for companies to innovate and expand their market reach. Timeline: Ongoing.
- Focusing on Personalized Nutrition: Stemtech can capitalize on the growing trend of personalized nutrition by offering customized dietary supplement solutions based on individual health needs and preferences. This includes developing diagnostic tools to assess stem cell health and formulating personalized supplement regimens. Timeline: Ongoing.
What Threats Does STEK Face?
- Competition from established dietary supplement brands.
- Regulatory scrutiny.
- Economic downturns.
- Changing consumer preferences.
What Are STEK's Competitive Advantages?
- Proprietary Formulations: Stemtech's science-based formulations provide a competitive advantage.
- Brand Recognition: Established brands like stemrelease3 and DermaStem.
- Focus on Stem Cell Nutrition: Niche market focus differentiates Stemtech from competitors.
What Does STEK Do?
Stemtech Corporation, established as a stem cell nutrition company, focuses on developing and distributing products designed to support the body's natural stem cell functions. The company's core philosophy revolves around enhancing stem cell physiology through science-based dietary supplements. These products are formulated to aid in the release, circulation, and migration of stem cells, facilitating tissue renewal and overall health. Stemtech's product line includes offerings under brands like the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze. The company operates primarily in the Americas, Latin America, and Asia, targeting consumers interested in natural health solutions. Stemtech's business model centers on providing dietary supplements that support stem cell activity, differentiating itself through a scientific approach to stem cell nutrition. Based in Miramar, Florida, Stemtech continues to navigate the competitive landscape of the dietary supplement industry, focusing on expanding its market reach and product innovation.
What Products and Services Does STEK Offer?
- Develops science-based products to support healthy stem cell physiology.
- Offers dietary supplements to enhance stem cell release.
- Aids in stem cell circulation within the bloodstream.
- Promotes stem cell migration into tissues for renewal.
- Markets products under brands like stemrelease3 and DermaStem.
- Operates in the Americas, Latin America, and Asia.
- Focuses on natural health solutions through stem cell nutrition.
How Does STEK Make Money?
- Develops and manufactures stem cell nutrition products.
- Markets and distributes products through various channels.
- Generates revenue through the sale of dietary supplements.
- Focuses on direct-to-consumer sales and partnerships.
What Industry Does STEK Operate In?
Stemtech Corporation operates within the dietary supplement industry, a segment of the broader healthcare market. This industry is characterized by increasing consumer interest in natural health solutions and preventive care. The competitive landscape includes established dietary supplement brands and companies focusing on stem cell-related products. Stemtech differentiates itself through its focus on stem cell nutrition and science-based formulations. The industry is subject to regulatory scrutiny, requiring companies to comply with health and safety standards. Market trends include a growing demand for personalized nutrition and innovative delivery systems.
Who Are STEK's Key Customers?
- Individuals seeking natural health solutions.
- Consumers interested in stem cell nutrition.
- Customers in the Americas, Latin America, and Asia.
- Health-conscious individuals looking for dietary supplements.
Insider Activity
The most recent 6 insider filings for Stemtech Corporation break down as 2 sales and 4 purchases. On net that is roughly 11.0M shares acquired (about $569K) — insiders putting money in tends to read as conviction.
Key Financial Metrics
Return on equity for Stemtech Corporation stands at 59.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -92.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Stemtech Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.89 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Stemtech Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Naples, US. The company is led by CEO Charles S. Arnold. STEK has traded publicly since 2021.
STEK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Science-based product formulations.
- Established brand recognition in niche market.
- Focus on stem cell nutrition.
- Presence in multiple geographic regions.
Bear Case
- Negative profit margin.
- Small market capitalization.
- Limited financial resources.
- Dependence on a niche market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
STEK Latest News
-
Streamex Announces 10M Buyback Plan At $2/Share
benzinga · Jul 7, 2026
STEK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for STEK.
Price Targets
Wall Street price target analysis for STEK.
STEK MoonshotScore
What does this score mean?
The MoonshotScore rates STEK 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Charles S. Arnold
CEO
Charles S. Arnold serves as the CEO of Stemtech Corporation, leading a team of one employee. Information regarding his detailed career history, education, and previous roles is not available. As CEO, he is responsible for the overall strategic direction and operational management of the company, focusing on the development and distribution of stem cell nutrition products.
Track Record: Due to limited information, Charles S. Arnold's specific achievements and milestones as CEO of Stemtech Corporation are unknown. His leadership is focused on navigating the competitive dietary supplement market and expanding the company's reach in the Americas, Latin America, and Asia.
STEK OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Stemtech Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures, increasing the risk for investors. Trading on the OTC Other tier differs significantly from exchanges like NYSE or NASDAQ, which have stricter listing requirements and greater regulatory oversight. This tier is generally reserved for distressed, defunct, or shell companies.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of transparency due to limited financial reporting.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Higher potential for price swings due to limited market participation.
- Regulatory Scrutiny: Potential for regulatory actions due to non-compliance with reporting requirements.
- Going Concern Risk: Uncertainty about the company's ability to continue operating.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive position.
- Evaluate the management team and their track record.
- Research any legal or regulatory issues.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Established Brand Recognition: Brand presence through products like stemrelease3 and DermaStem.
- Focus on Science-Based Formulations: Emphasis on scientific research and development.
- Geographic Presence: Operations in the Americas, Latin America, and Asia.
What Investors Ask About Stemtech Corporation (STEK) — Healthcare
What does Stemtech Corporation do?
Stemtech Corporation develops, markets, and sells dietary supplements focused on stem cell nutrition. Its products are designed to support the body's natural ability to renew and repair tissues by enhancing the release, circulation, and migration of stem cells. The company operates primarily in the Americas, Latin America, and Asia, offering products under brands like stemrelease3, DermaStem, and others.
What do analysts say about STEK stock?
Given that Stemtech Corporation trades on the OTC Other tier, formal analyst coverage is unlikely. Key valuation metrics, such as the negative P/E ratio, indicate that the company is currently not profitable. Growth considerations include expanding distribution networks and introducing new products.
What are the main risks for STEK?
Stemtech Corporation faces several risks, including intense competition from established dietary supplement brands, regulatory scrutiny typical of the healthcare sector, and operational inefficiencies impacting profitability. As an OTC-traded company, Stemtech is subject to limited financial disclosure and liquidity constraints, increasing the potential for price volatility. The company's small market capitalization and limited financial resources further amplify these risks. Investors should carefully consider these factors before investing in Stemtech.
How does Stemtech Corporation navigate regulatory approval processes?
As a dietary supplement company, Stemtech Corporation must comply with regulations set forth by various health authorities in the regions where it operates, including the FDA in the United States. While dietary supplements generally do not require the same pre-market approval as pharmaceutical drugs, Stemtech must ensure its products meet safety and labeling requirements.
How does Stemtech Corporation manage its supply chain?
Stemtech Corporation's supply chain management is critical to ensuring the quality and availability of its stem cell nutrition products. This involves sourcing raw materials from reputable suppliers, implementing quality control measures throughout the manufacturing process, and managing inventory levels to meet customer demand. The company likely relies on third-party manufacturers and distributors to produce and deliver its products to market.
What are the key factors to evaluate for STEK?
Evaluate STEK on fundamentals, analyst consensus, and risk factors. Stemtech Corporation operates in the niche market of stem cell nutrition, offering potential for growth within the broader dietary supplement industry. Not financial advice.
How frequently does STEK data refresh on this page?
STEK's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven STEK's recent stock price performance?
Stemtech Corporation (STEK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Science-based product formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- OTC market carries higher risk than major exchanges.
- Financial data may be limited or unaudited.